EMA Authorised: Vivlipeg (pegfilgrastim) — Biosimilar Collaborations Ireland Limited

View source ↗

Summary

The EMA authorised Vivlipeg, a biosimilar pegfilgrastim. The product is indicated for neutropenia and related febrile neutropenia in cancer patients, including …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Chemotherapy-induced Febrile Neutropenia
• Febrile Neutropenia
• Neutropenia

Drugs mentioned

• Vivlipeg (pegfilgrastim)

Snippet

Status: Authorised. Therapeutic area: Neutropenia;Febrile Neutropenia;Chemotherapy-Induced Febrile Neutropenia;Cancer. MAH: Biosimilar Collaborations Ireland Limited. Decision date: 23/02/2026